<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04872894</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-HCF-2020-89</org_study_id>
    <nct_id>NCT04872894</nct_id>
  </id_info>
  <brief_title>Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution</brief_title>
  <official_title>Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Familial hypocalciuric hypercalcemia (FHH) is a rare disease (ORPHA#405, www.orpha.net) and&#xD;
      most likely underdiagnosed, that clinicians should be aware of in the differential diagnosis&#xD;
      of a hypercalcemia. Appropriate identification of the FHH has implications in treatment and&#xD;
      also for the family, since it is an automosal-dominant disease, due to mostly a heterozygous&#xD;
      loss-of-function mutation of the CASR (calcium-sensing receptor) gene, but also much less&#xD;
      freqüent mutations of another two genes (AP2S1 and GNA11). In case of clinical and&#xD;
      biochemical suspicion of FHH, a genetic evaluation is mandatory. Nevertheless, an important&#xD;
      number of patients, the genetic study is negative. This observational study is intended to&#xD;
      perform a descriptive review of cases with clinical and biochemical suspicion of FHH who&#xD;
      underwent a genetic study in the usual clinical practice. Clinical, biochemical and&#xD;
      radiological characteristics, treatment, follow-up and comorbidities of genotype-negative&#xD;
      participants will be compared with genotype-positive cases.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Age (years)</measure>
    <time_frame>1 year</time_frame>
    <description>Clinical characteristics of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gender distribution (%)</measure>
    <time_frame>1 year</time_frame>
    <description>Of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcium levels (mg/dL)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Biochemical characteristics. Of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathyroid Ultrasound results</measure>
    <time_frame>1 year</time_frame>
    <description>Of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment modalities used</measure>
    <time_frame>1 year</time_frame>
    <description>Of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FHH associated comorbidities</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Of genotype-negative and genotype-positive participants with biochemical suspicion of FHH</description>
  </secondary_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Familial Hypocalciuric Hypercalcemia</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study. No intervention is performed</intervention_name>
    <description>Descriptive study in participants with clinical and biochemical suspicion of FHH. Comparison between genotype-negative and genotype-positive participants with clinical and biochemical suspicion of FHH.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with biochemical and clinical suspicion of FHH, namely hypercalcemia,&#xD;
        hypophospatemia, normal or elevated parathormone levels and very low urine calcium&#xD;
        excretion defined as a calcium creatinine clearance ratio &lt;0.01, and who were asked at&#xD;
        discretion of the clinician for a genetic evaluation of any of the FHH causing genes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with clinical and biochemical suspicion of FHH who, at the discretion of the&#xD;
             physician in routine clinical practice, were asked to perform a genetic evaluation of&#xD;
             FHH and whose genetic results are available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Genetic study of FHH is not available or was not performed despite clinical and&#xD;
             biochemical suspicion of FHH.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Anna Aulinas, MD PhD</last_name>
    <phone>+34932919000</phone>
    <phone_ext>7917</phone_ext>
    <email>aaulinas@santpau.cat</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Delgado</last_name>
    <phone>+34932919000</phone>
    <phone_ext>7634</phone_ext>
    <email>cdelgadoe@santpau.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Aulinas, MD PhD</last_name>
      <phone>+34932919000</phone>
      <phone_ext>7917</phone_ext>
      <email>aaulinas@santpau.cat</email>
    </contact>
    <contact_backup>
      <last_name>Claudia Delgado</last_name>
      <phone>+34932919000</phone>
      <phone_ext>7634</phone_ext>
      <email>cdelgadoe@santpau.cat</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypercalcemia</keyword>
  <keyword>Familial Benign Hypercalcemia</keyword>
  <keyword>Familial hypocalciuric hypercalcemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercalcemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

